548 related articles for article (PubMed ID: 29577340)
1. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis.
Chokesuwattanaskul R; Thongprayoon C; Tanawuttiwat T; Kaewput W; Pachariyanon P; Cheungpasitporn W
Pacing Clin Electrophysiol; 2018 Jun; 41(6):627-634. PubMed ID: 29577340
[TBL] [Abstract][Full Text] [Related]
2. Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease.
Sarratt SC; Nesbit R; Moye R
Ann Pharmacother; 2017 Jun; 51(6):445-450. PubMed ID: 28478715
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Apixaban, Rivaroxaban, and Warfarin in End-Stage Renal Disease With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Abdullah HM; Ullah W; Jafar MS; van Zyl M; Saeed R; Alam M; Alraies MC; Fischman DL
Cardiovasc Revasc Med; 2021 Sep; 30():26-32. PubMed ID: 34420589
[TBL] [Abstract][Full Text] [Related]
4. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.
Stanifer JW; Pokorney SD; Chertow GM; Hohnloser SH; Wojdyla DM; Garonzik S; Byon W; Hijazi Z; Lopes RD; Alexander JH; Wallentin L; Granger CB
Circulation; 2020 Apr; 141(17):1384-1392. PubMed ID: 32160801
[TBL] [Abstract][Full Text] [Related]
5. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
6. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Proietti M; Romanazzi I; Romiti GF; Farcomeni A; Lip GYH
Stroke; 2018 Jan; 49(1):98-106. PubMed ID: 29167388
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
Schafer JH; Casey AL; Dupre KA; Staubes BA
Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510
[TBL] [Abstract][Full Text] [Related]
8. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
10. Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital.
Herndon K; Guidry TJ; Wassell K; Elliott W
Ann Pharmacother; 2020 Jun; 54(6):554-560. PubMed ID: 31872779
[No Abstract] [Full Text] [Related]
11. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
[TBL] [Abstract][Full Text] [Related]
12. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.
Hijazi Z; Hohnloser SH; Andersson U; Alexander JH; Hanna M; Keltai M; Parkhomenko A; López-Sendón JL; Lopes RD; Siegbahn A; Granger CB; Wallentin L
JAMA Cardiol; 2016 Jul; 1(4):451-60. PubMed ID: 27438322
[TBL] [Abstract][Full Text] [Related]
14. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
De Caterina R; Andersson U; Alexander JH; Al-Khatib SM; Bahit MC; Goto S; Hanna M; Held C; Hohnloser S; Hylek EM; Lanas F; Lopes RD; López-Sendón J; Renda G; Horowitz J; Granger CB; Wallentin L;
Am Heart J; 2016 May; 175():175-83. PubMed ID: 27179738
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.
Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Delinger R; Yuce H; Luo X
Thromb Haemost; 2022 Jun; 122(6):926-938. PubMed ID: 34963185
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG
Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197
[TBL] [Abstract][Full Text] [Related]
17. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis.
Tan J; Liu S; Segal JB; Alexander GC; McAdams-DeMarco M
BMC Nephrol; 2016 Oct; 17(1):157. PubMed ID: 27769175
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis.
Moore M; Vizcaino K; Ewing JA; St Ville M
J Am Pharm Assoc (2003); 2024; 64(2):457-462. PubMed ID: 38151201
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
[TBL] [Abstract][Full Text] [Related]
20. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
